Xinhuanet, Beijing, March 5th. In response to the problem that domestic innovative drugs cannot be copied after their patents expire, Chen Baohua, a representative of the National People’s Congress and president of Huahai Pharmaceutical, suggested that the national drug regulatory department should speed up the revision and improvement of the current policies, so as to provide domestic products for domestic production. Create conditions for the imitation of innovative drugs, encourage the listing of generic drugs, and reduce the burden on the public and medical insurance.
In recent years, the number of domestic innovative drugs approved for marketing in my country has been increasing year by year. According to the statistics of Minenet, a professional research institution in the pharmaceutical market, since 2011, about 60 domestically produced Class 1 new drugs have been approved for marketing, and 11 of them will have a combined sales of more than 1 billion yuan in Chinese public medical institutions and Chinese urban physical pharmacies in 2020. .
Since most of the domestic innovative drugs are reimbursed by medical insurance, if they cannot be copied to encourage full competition, the price of drugs cannot be lowered, which is a huge burden to the people and medical insurance.
Chen Baohua said that the masses have extensive and urgent needs for domestic innovative drugs with clear curative effects. However, due to the constraints of current policies, domestic innovative drugs still cannot be copied after the patent expires. There is a phenomenon that a drug monopolizes the market for a long time after it is launched, forming a price and market monopoly. “This not only violates the purpose of medical reform such as improving the availability of drugs, reducing the burden of drug use and national medical insurance expenses, but also is inconsistent with the reform principle of the drug review system that encourages both innovation and imitation.” Chen Baohua said. “From the perspective of the urgent needs of the masses for drug use, the actual development of the pharmaceutical industry, and the practices of advanced countries and regions around the world, my country’s current drug management policies need to be revised and improved.” Chen Baohua said that it is recommended that the national drug regulatory authority should clarify the curative effect. . Domestic innovative drugs and improved new drugs whose patents have expired are directly assigned the status of reference preparations, and are included in the reference preparation catalogue for regular publicity, allowing other companies to imitate them, in order to break the market monopoly, improve the availability of drugs for patients, and reduce the burden of medical insurance. , to help promote the healthy China strategy.
(Reporters Dai Xiaohe and Xiong Feng)